These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26079332)

  • 41. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Gallina A
    Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
    [No Abstract]   [Full Text] [Related]  

  • 42. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
    Bartoletti R; Cai T
    Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
    [No Abstract]   [Full Text] [Related]  

  • 45. Active surveillance for prostate cancer: barriers to widespread adoption.
    Sandhu GS; Andriole GL
    Eur Urol; 2012 Dec; 62(6):984-5. PubMed ID: 22770662
    [No Abstract]   [Full Text] [Related]  

  • 46. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
    Thomsen FB; Røder MA; Hvarness H; Iversen P; Brasso K
    Dan Med J; 2013 Feb; 60(2):A4575. PubMed ID: 23461989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Significance of Change in Gleason Grade in Patients on Active Surveillance for Prostate Cancer.
    Marks LS
    J Urol; 2015 Jul; 194(1):8-9. PubMed ID: 25892137
    [No Abstract]   [Full Text] [Related]  

  • 48. The expanding role of body mass in active surveillance for prostate cancer.
    Ahearn TU; Shui IM; Giovannucci EL
    Eur Urol; 2014 Nov; 66(5):849-50. PubMed ID: 25037639
    [No Abstract]   [Full Text] [Related]  

  • 49. Words of wisdom. Re: Medium-term outcomes of active surveillance for localized prostate cancer.
    Mir MC; Stephenson AJ
    Eur Urol; 2013 Dec; 64(6):1013-4. PubMed ID: 24209447
    [No Abstract]   [Full Text] [Related]  

  • 50. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
    Bailey DE; Wallace M
    Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Words of wisdom. Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.
    Klaassen Z; Wyatt B; Moses KA; Terris MK
    Eur Urol; 2013 Nov; 64(5):855. PubMed ID: 24112612
    [No Abstract]   [Full Text] [Related]  

  • 52. Active surveillance helps prostate cancer patients keep quality of life, findings show.
    Printz C
    Cancer; 2017 Aug; 123(16):2997. PubMed ID: 28777452
    [No Abstract]   [Full Text] [Related]  

  • 53. [Not Available].
    Aktuelle Urol; 2015 May; 46(3):195-6. PubMed ID: 26077295
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical and policy perspectives on the adoption of active surveillance for low-risk prostate cancer.
    Frendl DM; Sokoloff MH
    Med Care; 2014 Jul; 52(7):576-8. PubMed ID: 24926703
    [No Abstract]   [Full Text] [Related]  

  • 55. Words of wisdom. Re: Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance.
    Rosen RC
    Eur Urol; 2014 Feb; 65(2):497-8. PubMed ID: 24407205
    [No Abstract]   [Full Text] [Related]  

  • 56. Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?
    Gnanapragasam VJ; Barrett T; Pacey S; Warren A
    BJU Int; 2021 Jun; 127(6):628-629. PubMed ID: 33774889
    [No Abstract]   [Full Text] [Related]  

  • 57. More US men with low risk prostate cancer opt for watchful waiting.
    McCarthy M
    BMJ; 2015 Jul; 351():h3777. PubMed ID: 26163150
    [No Abstract]   [Full Text] [Related]  

  • 58. [Cost effectiveness of various active surveillance strategies compared to watchful waiting].
    Othman A; Nikolaou K
    Urologe A; 2019 Sep; 58(9):1088-1089. PubMed ID: 31317212
    [No Abstract]   [Full Text] [Related]  

  • 59. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.
    Cooperberg MR; Carroll PR
    JAMA; 2015 Jul; 314(1):80-2. PubMed ID: 26151271
    [No Abstract]   [Full Text] [Related]  

  • 60. You're kidding...I have cancer? A patient's perspective on coping with prostate cancer and why active surveillance was not chosen.
    Lipton DA
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):140-2. PubMed ID: 23271763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.